Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomy1-Testosterone
Identification
- Name
- 1-Testosterone
- Accession Number
- DB01481
- Type
- Small Molecule
- Groups
- Experimental, Illicit, Investigational
- Description
1-Testosterone is an anabolic steroid that differs from testosterone by having a 1,2-double bond instead of 4,5-double bond in its A ring.
- Structure
Structure for 1-Testosterone (DB01481)
- Synonyms
- 1-T
- 1-Testo
- 17beta-hydroxy-5alpha-androst-1-en-3-one
- Androstendolone
- delta1-Dihydrotestosterone
- External IDs
- J108.132B
- Categories
- UNII
- Y984BV1Q0G
- CAS number
- 65-06-5
- Weight
- Average: 288.4244
Monoisotopic: 288.20893014 - Chemical Formula
- C19H28O2
- InChI Key
- OKJCFMUGMSVJBG-ABEVXSGRSA-N
- InChI
- InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,12,14-17,21H,3-6,8,10-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1
- IUPAC Name
- (1S,2R,7S,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-3-en-5-one
- SMILES
- [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C=C[C@]12C
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
Delta1-dihydrotestosterone binds to the androgen receptor, a nuclear receptor which binds the androgenic hormones testosterone and dihydrotestosterone. Once bound, the receptor/ligand complex localizes to the nucleus and acts as a DNA binding transcription factor, regulating gene expression. In animals, Delta1-dihydrotestosterone stimulates the growth of the prostate as well as the seminal vesicles.
- Mechanism of action
Delta1-dihydrotestosterone binds to the androgen receptor, a nuclear receptor which binds the androgenic hormones testosterone and dihydrotestosterone. Once bound, the receptor/ligand complex localizes to the nucleus and acts as a DNA binding transcription factor, regulating gene expression.
Target Actions Organism AAndrogen receptor agonistHumans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction (R)-warfarin The therapeutic efficacy of (R)-warfarin can be increased when used in combination with 1-Testosterone. (S)-Warfarin The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with 1-Testosterone. 4-hydroxycoumarin The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with 1-Testosterone. Abciximab The therapeutic efficacy of Abciximab can be increased when used in combination with 1-Testosterone. Acenocoumarol The therapeutic efficacy of Acenocoumarol can be increased when used in combination with 1-Testosterone. Acetylsalicylic acid The therapeutic efficacy of Acetylsalicylic acid can be increased when used in combination with 1-Testosterone. Aldosterone The risk or severity of edema formation can be increased when 1-Testosterone is combined with Aldosterone. Alteplase The therapeutic efficacy of Alteplase can be increased when used in combination with 1-Testosterone. Amediplase The therapeutic efficacy of Amediplase can be increased when used in combination with 1-Testosterone. Anagrelide The therapeutic efficacy of Anagrelide can be increased when used in combination with 1-Testosterone. - Food Interactions
- Not Available
References
- General References
- Friedel A, Geyer H, Kamber M, Laudenbach-Leschowsky U, Schanzer W, Thevis M, Vollmer G, Zierau O, Diel P: 17beta-hydroxy-5alpha-androst-1-en-3-one (1-testosterone) is a potent androgen with anabolic properties. Toxicol Lett. 2006 Aug 20;165(2):149-55. Epub 2006 Apr 18. [PubMed:16621347]
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count Not Available Unknown Status Treatment Restless Legs Syndrome (RLS) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0128 mg/mL ALOGPS logP 3.38 ALOGPS logP 3.41 ChemAxon logS -4.4 ALOGPS pKa (Strongest Acidic) 19.38 ChemAxon pKa (Strongest Basic) -0.88 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 37.3 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 84.7 m3·mol-1 ChemAxon Polarizability 34.06 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9835 Caco-2 permeable + 0.8943 P-glycoprotein substrate Substrate 0.6036 P-glycoprotein inhibitor I Non-inhibitor 0.5133 P-glycoprotein inhibitor II Non-inhibitor 0.8114 Renal organic cation transporter Non-inhibitor 0.791 CYP450 2C9 substrate Non-substrate 0.7459 CYP450 2D6 substrate Non-substrate 0.9292 CYP450 3A4 substrate Substrate 0.7431 CYP450 1A2 substrate Non-inhibitor 0.7338 CYP450 2C9 inhibitor Non-inhibitor 0.9397 CYP450 2D6 inhibitor Non-inhibitor 0.9672 CYP450 2C19 inhibitor Non-inhibitor 0.8086 CYP450 3A4 inhibitor Non-inhibitor 0.8474 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.933 Ames test Non AMES toxic 0.9268 Carcinogenicity Non-carcinogens 0.9287 Biodegradation Not ready biodegradable 0.983 Rat acute toxicity 2.0714 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9314 hERG inhibition (predictor II) Non-inhibitor 0.6661
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Androstane steroids
- Direct Parent
- Androgens and derivatives
- Alternative Parents
- 3-oxo-5-alpha-steroids / 3-oxo delta-1-steroids / 17-hydroxysteroids / Delta-1-steroids / Cyclohexenones / Secondary alcohols / Cyclic alcohols and derivatives / Organic oxides / Hydrocarbon derivatives
- Substituents
- Androgen-skeleton / 3-oxo-delta-1-steroid / 3-oxosteroid / 3-oxo-5-alpha-steroid / 17-hydroxysteroid / Oxosteroid / Hydroxysteroid / Delta-1-steroid / Cyclohexenone / Cyclic alcohol
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- 17beta-hydroxy steroid, 3-oxo Delta(1)-steroid, anabolic androgenic steroid (CHEBI:59714)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
- Gene Name
- AR
- Uniprot ID
- P10275
- Uniprot Name
- Androgen receptor
- Molecular Weight
- 98987.9 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Friedel A, Geyer H, Kamber M, Laudenbach-Leschowsky U, Schanzer W, Thevis M, Vollmer G, Zierau O, Diel P: 17beta-hydroxy-5alpha-androst-1-en-3-one (1-testosterone) is a potent androgen with anabolic properties. Toxicol Lett. 2006 Aug 20;165(2):149-55. Epub 2006 Apr 18. [PubMed:16621347]
Drug created on July 31, 2007 07:09 / Updated on November 02, 2018 05:01